169 related articles for article (PubMed ID: 38698123)
1. Preparation and characterization of artemether-loaded niosomes in Leishmania major-induced cutaneous leishmaniasis.
Niroumand U; Motazedian MH; Ahmadi F; Asgari Q; Bahreini MS; Ghasemiyeh P; Mohammadi-Samani S
Sci Rep; 2024 May; 14(1):10073. PubMed ID: 38698123
[TBL] [Abstract][Full Text] [Related]
2. A novel delivery of curcumin by the efficient nanoliposomal approach against
Fattahi Bafghi A; Haghirosadat BF; Yazdian F; Mirzaei F; Pourmadadi M; Pournasir F; Hemati M; Pournasir S
Prep Biochem Biotechnol; 2021; 51(10):990-997. PubMed ID: 34060984
[TBL] [Abstract][Full Text] [Related]
3. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
[TBL] [Abstract][Full Text] [Related]
4. Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis.
Dar MJ; McElroy CA; Khan MI; Satoskar AR; Khan GM
Expert Opin Drug Deliv; 2020 Jan; 17(1):97-110. PubMed ID: 31786952
[No Abstract] [Full Text] [Related]
5. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
6. The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.
Moosavian SA; Fallah M; Jaafari MR
Exp Parasitol; 2019 May; 200():30-35. PubMed ID: 30898544
[TBL] [Abstract][Full Text] [Related]
7. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
[TBL] [Abstract][Full Text] [Related]
8. Anti-leishmanial effects of resveratrol and resveratrol nanoemulsion on Leishmania major.
Mousavi P; Rahimi Esboei B; Pourhajibagher M; Fakhar M; Shahmoradi Z; Hejazi SH; Hassannia H; Nasrollahi Omran A; Hasanpour H
BMC Microbiol; 2022 Feb; 22(1):56. PubMed ID: 35168553
[TBL] [Abstract][Full Text] [Related]
9. Artemether-loaded nanostructured lipid carriers: preparation, characterization, and evaluation of
Rahnama V; Motazedian MH; Mohammadi-Samani S; Asgari Q; Ghasemiyeh P; Khazaei M
Res Pharm Sci; 2021 Dec; 16(6):623-633. PubMed ID: 34760010
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
11. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
12. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
13. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
[TBL] [Abstract][Full Text] [Related]
14. Fe3O4
Albalawi AE; Khalaf AK; Alyousif MS; Alanazi AD; Baharvand P; Shakibaie M; Mahmoudvand H
Biomed Pharmacother; 2021 Jul; 139():111566. PubMed ID: 33839494
[TBL] [Abstract][Full Text] [Related]
15. Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis.
Momeni A; Rasoolian M; Momeni A; Navaei A; Emami S; Shaker Z; Mohebali M; Khoshdel A
J Liposome Res; 2013 Jun; 23(2):134-44. PubMed ID: 23350940
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of
Anjum A; Shabbir K; Din FU; Shafique S; Zaidi SS; Almari AH; Alqahtani T; Maryiam A; Moneeb Khan M; Al Fatease A; Bashir S; Khan GM
Drug Deliv; 2023 Dec; 30(1):2173335. PubMed ID: 36722301
[TBL] [Abstract][Full Text] [Related]
17. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell.
Dar MJ; Din FU; Khan GM
Drug Deliv; 2018 Nov; 25(1):1595-1606. PubMed ID: 30105918
[TBL] [Abstract][Full Text] [Related]
18. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
Bemani E; Oryan A; Bahrami S
Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
[TBL] [Abstract][Full Text] [Related]
20. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
